{"id":"NCT00739973","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension","officialTitle":"An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2008-08-22","resultsPosted":"2011-05-03","lastUpdate":"2011-06-06"},"enrollment":2694,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Aliskiren 150 mg tablet","otherNames":[]},{"type":"DRUG","name":"Aliskiren 300 mg tablet","otherNames":[]},{"type":"DRUG","name":"Amlodipine 5 mg capsule","otherNames":[]},{"type":"DRUG","name":"Amlodipine 10 mg capsule","otherNames":[]},{"type":"DRUG","name":"Aliskiren/amlodipine 150/5 mg tablet","otherNames":[]},{"type":"DRUG","name":"Aliskiren/amlodipine 150/10 mg tablet","otherNames":[]},{"type":"DRUG","name":"Aliskiren/amlodipine 300/5 mg tablet","otherNames":[]},{"type":"DRUG","name":"Aliskiren/amlodipine 300/10 mg tablet","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Aliskiren 150 mg tablet","type":"EXPERIMENTAL"},{"label":"Aliskiren 300 mg tablet","type":"EXPERIMENTAL"},{"label":"Amlodipine 5 mg capsule","type":"EXPERIMENTAL"},{"label":"Amlodipine 10 mg capsule","type":"EXPERIMENTAL"},{"label":"Aliskiren/amlodipine 150/5 mg tablet","type":"EXPERIMENTAL"},{"label":"Aliskiren/amlodipine 150/10 mg tablet","type":"EXPERIMENTAL"},{"label":"Aliskiren/amlodipine 300/5 mg tablet","type":"EXPERIMENTAL"},{"label":"Aliskiren/amlodipine 300/10 mg tablet","type":"EXPERIMENTAL"}],"summary":"Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.","primaryOutcome":{"measure":"Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP)","timeFrame":"Baseline to end of study (Week 8)","effectByArm":[{"arm":"Aliskiren 150 mg","deltaMin":-7.99,"sd":0.63},{"arm":"Aliskiren/Amlodipine 150/5 mg","deltaMin":-13.98,"sd":0.66}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":18,"countries":["United States","Argentina","Australia","Canada","Colombia","Denmark","Finland","Greece","Italy","Mexico","Panama","Peru","Romania","Russia","South Africa","Spain","Sweden","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":198},"commonTop":["Headache","Oedema peripheral"]}}